Arne Slungaard, MD

Professor of Medicine, Division of Hematology, Oncology and Transplantation

Arne Slungaard

Contact Info

Mailing Address:
Division of Hematology, Oncology and Transplantation
420 Delaware Street SE
MMC 480
Minneapolis, MN 55455

Administrative Assistant Name
Kris Blomquist

Administrative Phone
612-625-8942

Administrative Email
krblomqu@umn.edu

Administrative Fax Number
612-625-6919

Professor of Medicine, Division of Hematology, Oncology and Transplantation


Hematologist


Medical School, University of Minnesota, Minneapolis, MN

Residency, University of Minnesota, Minneapolis, MN

Fellowship, University of Minnesota, Minneapolis, MN

Summary

Dr. Slungaard received his B.A. from Carleton College, Northfield, Minnesota and his M.D., residency, and Hematology and Oncology subspecialty training at the University of Minnesota. He joined the faculty in 1984. He is the coordinator of Grand Rounds for the Division of Hematology, Oncology and Transplantation.

Research

Research Summary/Interests

Dr. Slungaard’s clinical interest is in bone marrow and peripheral blood stem cell transplantation. His research interests are the biology and pathology of eosinophil peroxidase-mediated oxidant tissue damage and interactions of cationic proteins such as platelet factor 4 with the thrombomodulin/protein C natural anticoagulant system.

Publications

  • McClune BL, Defor T, Brunstein C, Vogel RI, Majhail NS, Bachanova V, Burns LJ, Slungaard A, Weisdorf DJ. Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting. Br J Haematol. 2012; 156(2):273-5. PMID: 21923655
  • Warlick ED, Tomblyn M, Cao Q, Defor T, Blazar BR, Macmillan M, Verneris M, Wagner J, Dusenbery K, Aurora M, Bachanova V, Brunstein C, Burns L, Cooley S, Kaufman D, Majhail NS, McClune B, McGlave P, Miller J, Oran B, Slungaard A, Vercellotti G, Weisdorf DJ. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-hodgkin lymphomas. Biol Blood Marrow Transplant. 2011 Jul;17(7):1025-32.
  • Zhang W, Wang J, Wang H, Tang R, Belcher JD, Viollet B, Geng JG, Zhang C, Wu C, Slungaard A, Zhu C, Huo Y. Acadesine inhibits tissue factor induction and thrombus formation by activating the phosphoinositide 3-kinase/Akt signaling pathway. Arterioscler Thromb Vasc Biol. 2010 May;30(5):1000-6.
  • Hebbel RP, Vercellotti GM, Pace BS, Solovey AN, Kollander R, Abanonu CF, Nguyen J, Vineyard JV, Belcher JD, Abdulla F, Osifuye S, Eaton JW, Kelm RJ Jr, Slungaard A. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood. 2010 Mar 25;115(12):2483-90.
  • Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, Defor TE, Dusenbery KE, Kaufman DS, Kersey JH, Macmillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: Analysis of graft sources and long-term outcome. J Clin Oncol. 2009; 27(22): 3634-41. PMID: 19581540
  • Li YD, Ye BQ, Zheng SX, Wang JT, Wang JG, Chen M, Liu JG, Pei XH, Wang LJ, Lin ZX, Gupta K, Mackman N, Slungaard A, Key NS, Geng JG. NF-kappa B transcription factor p50 critically regulates tissue factor in deep vein thrombosis. J Biol Chem. 2009; 284(7):4473-83. PMID: 19095643
  • Wang J, Slungaard A. Role of eosinophil peroxidase in host defense and disease pathology. Arch Biochem Biophys 2006; 445: 256-60. (review).
  • Wang JG, Mahmud SA, Thompson JA, Geng JG, Key NS, Slungaard A. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood 2006; 107: 558-65.
  • Tan PL, Wagner JE, Auerbach AD, Defor TE, Slungaard A, Macmillan ML. Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation. Pediatr Blood Cancer 2006; 46: 630-6.
  • Nesmelova IV, Sham Y, Dudek AZ, van Eijk LI, Wu G, Slungaard A, Mortari F, Griffioen AW, Mayo KH. Platelet factor 4 and interleukin-8 CXC chemokine heterodimer formation modulates function at the quaternary structural level. J Biol Chem 2005; 280: 4948-58.

Clinical

Clinics

Blood and Marrow Transplant (BMT) Clinic;Masonic Cancer Center

Clinical Interests

Bone marrow transplantation; Peripheral blood stem cell transplantation; Leukemia